| SBHMY Stock | | | USD 15.89 0.00 0.00% |
This pattern recognition tool runs Rising and Falling Three Methods recognition and companion studies for Sino Biopharmaceutica. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for Sino Biopharmaceutica.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was fourteen with a total number of output elements of forty-seven. The function did not return any valid pattern recognition events for the selected time horizon. The Rising/Falling Three Methods may indicate that Sino Biopharmaceutical has been in a downtrend and is about to experience bullish continuation signal
Most technical analysis of Sino Biopharmaceutica help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Sino from various momentum indicators to cycle indicators. When you analyze Sino charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Sino Biopharmaceutical is scheduled to announce its earnings this week.Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States. Market structure and macro sensitivity help explain how Sino Biopharmaceutica behaves across regimes. Price movements may be comparatively less responsive to macroeconomic volatility. Sino Biopharmaceutica has a market cap of 10.88 B, P/E of 8.95, ROE of 29.08%.
Methodology
Unless otherwise specified, financial data for Sino Biopharmaceutical Ltd is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Sino (USA Stocks:SBHMY) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Sino Biopharmaceutical Ltd may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial Board
Tracking Sino Biopharmaceutica inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Financial ratios for Sino Biopharmaceutica help frame valuation context across profits, cash flow, and enterprise value. They help compare Sino across valuation measures and peers.